Company profile
Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Evruleucel | phase1_2 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06256484 | phase1 | terminated | 2024-09-06 | 2025-03-03 | Atara Biotherapeutics | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma |
| NCT06429800 | phase1 | withdrawn | 2025-04-16 | 2025-04-16 | Atara Biotherapeutics | A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus |
| NCT00002663 | phase1_2 | completed | 1995-03-01 | 2019-07-01 | Atara Biotherapeutics | Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies |
| NCT03283826 | phase1_2 | terminated | 2017-10-19 | 2023-11-09 | Atara Biotherapeutics | Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis |
| NCT03769467 | phase1_2 | terminated | 2019-02-19 | 2021-08-19 | Atara Biotherapeutics | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) |
FDA applications (0)
No records yet.